Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde et al. · New England Journal of Medicine · 2021 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Javier Cortés, Joyce O’Shaughnessy, David Loesch et al. · The Lancet · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +9

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology · 2019 · 772 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet · 2016 · 766 citations · Full text

Medicine, Oncology, Pharmacology +12